ALGS
Aligos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.02
+5.68%Year over year
Reported trailing growth
- Revenue
- +893.0%
- EBITDA
- —
- EBIT
- -0.6%
- EPS
- +41.9%
- Free cash flow
- -25.8%
- Operating cash flow
- -25.7%
Forward estimates
Based on analyst estimates
- Revenue
- -94.0%
- EBITDA
- +2.2%
- EPS
- +7.9%
Three-year CAGR
- Revenue
- -46.0%
- EBITDA
- +82.1%
- EBIT
- +1.3%
- Net income
- +81.6%
- EPS
- +88.3%
- Free cash flow
- -2.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026